A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

Summary

The purpose of this study is to evaluate the safety and tolerability of GS-9411 in patients with Cystic Fibrosis. GS-9411 is a sodium channel inhibitor, that may restore airway hydration and mucociliary clearance in the lung.

Timeline

Start

2009-12

Primary completion

2010-03

Completion

2010-04

Outcome

Outcome not reported

Stopped: “Development program terminated.”

Drugs

Indications